Expanded ALS drug coverage in B.C.

The Ministry of Health will provide coverage of edaravone, or Radicava, for patients living with amyotrophic lateral sclerosis (ALS, commonly called Lou Gehrig’s disease) upon conclusion of negotiations with its manufacturer as of Aug. 19, 2020.

In British Columbia, approximately 480 people have been diagnosed with ALS. ALS is a fatal neurodegenerative disease where patients typically become unable to move, speak, swallow and breathe as the condition progresses. In one clinical trial, edaravone has helped slow the worsening of this disease in a select ALS patient subpopulation.

Edaravone has been under pan-Canadian Pharmaceutical Alliance (pCPA) negotiation since September 2019. The negotiations between the manufacturer, Mitsubishi Tanabe Pharma Corporation, and the pCPA meet B.C.’s cost-related mandate.

“The offer from Mitsubishi Tanabe Pharma Corporation meets British Columbia’s criteria, which is great news for patients suffering from this deadly disease,” said Adrian Dix, Minister of Health. “B.C. will continue to support ALS patients through its expansion of coverage of life-changing drugs and research funding to improve the lives of British Columbians.”